This study is in progress, not accepting new patients
A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
Summary
- Eligibility
- for people ages 18-55 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Genentech, Inc.
- ID
- NCT00676715
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- About 220 people participating
- Last Updated